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ABSTRACT 
 
Background: Dendritic cells (DCs) play a central role in the initiation and expansion of 
T cell mediated immune responses with potential immunotherapy application. The 
compounds which have the ability to induce immunomodulatory effects on DCs may be 
employed for the treatment of immunopathologic conditions such as autoimmune dis-
eases. Objective: The aim of this study was to investigate the in vivo effects of calcit-
riol (active form of vitamin D3) on DCs. Methods: 0.1 microgram calcitriol was in-
jected intra-peritoneally into C57BL/6 mice every other day within 3 weeks, and spleen 
DCs were extracted by magnetic beads. The phenotypic and functional properties of 
DCs were studied by flow cytometry and mixed lymphocyte reaction (MLR), respec-
tively. Results: The expression of CD86 and MHC II, as maturation markers and 
costimulatory molecules were significantly decreased (p=0.028 and p=0.047, respec-
tively) while CD11b expression, as a marker of mice myeloid DCs which mostly in-
duces Th2 cytokine profile, was significantly increased (p=0.011). Allogeneic T cell 
stimulation in MLR was also significantly inhibited in comparison with the control 
groups (p<0.05). Conclusion: Our data indicate that in vivo calcitriol administration 
inhibits maturation and activation of DCs in the same manner as in vitro conditions. 
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INTRODUCTION 
 
As antigen processors, DCs possess an important role in the management of immune 
response. Based on this fact, scientists are aiming at manipulation of the immune re-
sponse towards preferred directions, using compounds which alter the functional prop-
erties of these crucial cells. Both in mice and human, there are two subtypes of dendritic 
cells, conventional (cDC) and plasmacytoid DCs (pDC) (1,2). 
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Spleen DCs are recognized by the expression of CD11c as a common marker for all 
subsets of these cells while on the basis of CD4, CD8α and CD11b expression, three 
subtypes of cDCs have been identified in this organ: CD4+ CD8α - CD11b+ (Myeloid) 
and CD8α + CD4- CD11b- (Lymphoid) DCs that localize mostly in the marginal zone 
and the T-cell zone, respectively. CD4- CD8α- CD11b+ DCs have also been identified 
and are called double-negative DCs (2,3). DC subtypes have different and in some as-
pects partially opposed phenotypic and functional properties. Lymphoid DCs in mice 
after antigen presentation and secretion of high amounts of IL-12 and IFN-γ, lead im-
mune response towards Th1 pathway, whereas myeloid ones shift immune function to 
Th2 type and produce IL-4 and IL-10 cytokines (in contrast to human DC subpopula-
tions). It is evident that induction of Th2 pathway by an appropriate DC subtype can be 
effective and useful in prevention and treatment of Th1-dependent autoimmune dis-
eases, such as multiple sclerosis (4-8). 
1,25 Dihydroxycholecalciferol (calcitriol), the active form of vitamin D3, has a crucial 
physiologic and hormonal role in the body. Although vitamin D3 is provided through 
diet but it is mostly made by the skin through the action of light. Exposure of skin to 
ultraviolet (UV) light causes the first step of vitamin D3 production. In this stage 7-
dehydrocholestrol is converted to pre-vitamin D3, and then vitamin D3 is produced 
spontaneously through a temperature dependent reaction. To gain biologically active 
form of vitamin D3, this compound must be hydroxylated in the liver and kidney by 
D3-25-hydroxylase and 25 OHD3-1-α-hydroxylase, respectively, resulting in produc-
tion of calcitriol as the active form of this vitamin. Apart from this classical metabolic 
pathway, several cells such as monocytes/macrophages, pneumocytes and keratinocytes 
can synthesize calcitriol (9-12). 
Calcitriol and its synthetic analogues such as TX527 have regulatory effects on immune 
system and are signified as immunomodulatory agents. These regulatory effects are ex-
erted after attachment of these compounds to their specific receptors (Vitamin D Recep-
tor = VDR), a member of the superfamily of nuclear hormone receptors, on target cells 
such as T, B, NK cells, DCs etc. (9,12-16). Furthermore it has been shown that VDR is 
constitutively expressed on antigen presenting cells but is also inducible by lympho-
cytes (9-14). Calcitriol reduces the production of Th1-dependent and inflammatory cy-
tokines such as IL-1, IL-2, IL-6, IL-12, TNF-α and IFN-γ downstream of its effects on 
T cells and monocytes. Similar in vitro effects on DCs are reported experiments as well 
(9, 16-19). Because in vivo cellular interactions and microenvironmental conditions are 
completely different from in vitro ones and considering the importance of these critical 
determinants in the course of immune response, it seems that we cannot generalize the 
in vitro observations to in vivo conditions. Therefore, we decided to investigate the in 
vivo effects of calcitriol on DC phenotype and function. 
 
 
MATERIALS AND METHODS 
 
Animals. 6-8 weeks old C57BL/6 female mice were obtained from Pasteur Institute of 
Iran. Mice were kept under optimal conditions of hygiene, temperature, and humidity 
with 12 hours of light and 12 hours of darkness cycle and were allowed food and water 
ad libitum. All experimental procedures on animals were approved by the ethical com-
mittee of Faculty of Medical Sciences, Tarbiat Modares University.   
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Treatments. 0.1 microgram calcitriol (Sigma, USA) was injected intra-peritoneally 
every other day within 3 weeks (20,21). The mice in the control group were treated with 
2% ethanol in PBS as vehicle. Each group consisted of 6 age-matched female mice. 
Purification of Splenic DCs. This step was done according to our previous report (22) 
and using cell separation columns according to manufacturer's instruction. Briefly, 
spleens of the control and test mice were isolated and minced to very small pieces. The 
spleen tissues were suspended in cold (4˚C) PBS containing 1.2 mg/ml collagenase D 
(Roche, Germany). After incubation at 37˚C for 40 minutes, the collagenase was inacti-
vated by EDTA and the cells suspension was passed through a cell mesh and the col-
lected cells were washed twice. Mononuclear cells (MNC) were then separated by Ny-
codenz (Axis-shield, Norway); a material used in density gradient cell separation tech-
niques. The MNCs were then washed three times and incubated for 25 minutes at 4°C 
with 2.5% mice serum to block the non-specific binding sites. Anti-CD11c magnetic 
beads (Miltenyi Biotech, Germany) were added to the cells and incubated at 4°C for 30 
minutes and the non-bonded antibodies were washed out. The minimacs separator (MS) 
cell columns were put into the magnetic field (MS separation unit, Miltenyi Biotech, 
USA) and washed by 1.5 ml EDTA-containing PBS.  
The cell suspension was then passed through the column to absorb the magnetic bead 
coated DCs and the unwanted cells were washed out using at least 3 washes of 500 µl 
EDTA-containing PBS. The isolated DCs were collected by disconnecting the column 
from the magnetic field and injecting it with 1 ml PBS-EDTA under pressure. 
Two-Color Flow Cytometric Analysis. The expression of phenotypic and maturation 
markers on the isolated dendritic cells was analyzed by flow cytometry. Simply, 1 µl of 
FITC conjugated anti- CD8α, CD11b, MHC II, CD40 and CD86 (BD biosciences, 
USA) or relevant isotype controls, was added to separate flow cytometry tubes contain-
ing 5×104 cells. After 15 min incubation on ice and in dark, 1 µl of PE conjugated anti-
CD11c (BD biosciences, USA) was added to all the tubes which were incubated under 
the same conditions for another 30 minutes.  
The cells were then washed by PBS and fixed by 2% paraformaldehyde before flow cy-
tometric analysis by FACScan flow cytometer (BD biosciences, USA). The results were 
analyzed by WinMDI software. Purity of isolated DC's was confirmed by staining them 
only with PE conjugated anti-CD11c. The cells stained with appropriate FITC or PE 
conjugated irrelevant antibodies were used as isotype controls.   
Mixed Lymphocyte Reaction (MLR). 1.5×104 separated and γ-irradiated (3000 rad) 
DCs were cultured in triplicate in 96-well plates (Nunc, Denmark) together with 
1.5×105 allogeneic T cells. The T cells were obtained and purified by passage of a sin-
gle cell suspension of BALB/c mice lymph nodes over a nylon wool column. The purity 
of T cell preparations were determined by flow cytometry as CD3+ cells and were rou-
tinely more than 90%. After 54 hours of incubation at 37°C and 5% CO2, 1 µCi 3H-
Thymidine (Amersham Biosciences, UK) was added to all wells. On the 3rd day of cul-
ture, the cells were harvested on glass fiber filter papers and their proliferation was 
measured in a liquid scintillation counter (Wallac, Pharmacia, Sweden). Results were 
expressed as the mean count per minutes (CPM) of the triplicate cultures. T cells cul-
tured in the presence of PHA as a polyclonal activator and DC or T cells alone were 
considered as positive and negative controls, respectively.  
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Statistical Analysis: Results are presented as Mean ± SD of at least six different ex-
periments. Mann-Whitney test was used for the evaluation of statistical differences be-
tween the results and p values less than 0.05 were considered statistically significant. 
 
 
RESULTS 
 
Separation of DCs. DCs were separated from the spleens of C57BL/6 mice through 
enzyme digestion followed by positive selection using anti-CD11c coated magnetic 
beads. The purity of DCs was determined as 91.28 ± 1.11% of separated cells using 
flow cytomety (Figure 1).  
 
 
 
 
 
 
 
 
 
Figure 1. Flowcytometric analysis of DCs. PE conjugated anti-CD11c staining and flowcytome-
try was used for determining the purity of isolated DCs. The histogram shows a representative 
of 12 separate experiments.  
 
Immunophenotypic Studies. The percentage of maturation and the co-stimulatory 
markers-bearing DCs was determined by two color flow cytometry. The expression den-
sity of studied molecules was also verified as mean fluorescent intensity (MFI). In vivo 
calcitriol-treated DCs, showed reduced percentages of positive cells and particularly 
lower expression of CD40, CD86, and MHC class II as maturation markers and lower 
expression of CD8α as a marker for lymphoid subsets of DCs which induce Th1 re-
sponses in mice, while CD11b expression which is considered as a marker of mouse 
myeloid DCs that mostly induce Th2 responses, was increased (Figures 2 and 3). 
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Figure 2.  Immunophenotyping of calcitriol treated DCs. Mice were treated with calcitriol for 
three weeks. Dendritic cells were separated from calcitriol treated and non-treated mice and the 
expression of subtypes and maturation markers were determined on CD11c+ DCs. The per-
centage of positive cells and Mean Fluorescent Intensity (MFI) of studied markers has been 
shown as Mean ± SD of 6 independent experiments. 
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Figure 3. The expression intensity of studied molecules on calcitriol treated and non-treated 
DCs. The density of subtypes and maturation markers on DCs was determined as Mean Fluo-
rescent Intensity (MFI). The histograms show the MFI of surface markers as Mean and SD of 
six independent experiments in each group.  
(P values: CD8α=0.117, CD40=0.251, CD11b=0.011, MHC class II=0.047 and CD86=0.028) 
 
Statistical analysis of the results showed that in vivo treatment by calcitriol does not af-
fect the percentage of marker-bearing cells significantly (p>0.05), whereas it causes a 
significant (p<0.05) decrease in the expression level (MFI) of all markers studied except 
CD8α and CD40. Furthermore spleen size was smaller in calcitriol treated mice com-
pared with the control group (data not shown). 
Mixed Leukocyte Reaction (MLR). We attempted to investigate the immunostimula-
tory potential of isolated DCs by standard MLR test. Gamma irradiated DCs from cal-
citriol treated and untreated mice were co-cultured with allogeneic T cells. The T cell 
stimulation and proliferation was measured through 3H-Thymidine incorporation. Statis-
tical analysis indicated a significant (p=0.004) decrease in the T cell stimulation poten-
tial of DCs from calcitriol treated mice (CPM = 25397 ± 855) in comparison with DCs 
from untreated mice (CPM = 31921 ± 1289). 
 
 
DISCUSSION  
 
Several effects on immune cells as well as on DCs have been reported for calcitriol; the 
natural active form of vitamin D3 (9,12-16). Indeed, almost all studies on the effects of 
vitamin D3 on DCs were performed in vitro (9,16-19,23,24). In this study, we tried to 
address the in vivo effects of calcitriol on DCs. Our results showed that although the 
changes in the relative percentage of the marker-positive DCs, after their in vivo treat-
ments by calcitriol compared with untreated DCs, were not statistically significant, the 
expression of most markers on the cell surface was significantly changed. In fact in vivo 
calcitriol treated DCs showed lower state of maturation which appeared as lower ex-
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pression of their maturation markers of CD40, CD86, and MHC II. However, the de-
crease in CD40 expression was not statistically significant.  
Moreover, calcitriol treated DCs showed a lower ability for T cell stimulation than the 
non-treated cells. In fact, the CPM of allogenic MLR in calcitriol treated groups (25397 
± 855) was significantly lower than the untreated controls (31921 ± 1289). 
Consistent to our findings Penna et al. (11) and Berer et al. (9) reported that human DCs 
are amongst the major targets for in vitro induced immunosuppressive activity of calcit-
riol. They showed that the presence of calcitriol during LPS-induced maturation of 
monocyte derived DCs caused downregulation in DC maturation which appeard as a 
high CD1a and a low CD83 expression. Moreover, the expression of costimulatory 
molecules CD40, CD80, CD86 and MHC II was inhibited. They also demonstrated that 
calcitriol has a suppressive effect on the human DC allostimulation of T cells in al-
logenic MLR.  This effect was accompanied by a decrease in IL-12 production and an 
increased secretion of IL-10.  
Van Halteren et al. (25) and Gauzzi et al. (26), also studied the in vitro effects of 
TX527, a vitamin D3 analogue, on DC differentiation, maturation and function. Con-
tinuous addition of TX527 to the cell culture impaired IL-4 and GM-CSF induced DC 
differentiation as well as LPS and IFN-γ induced DC maturation. They demonstrated 
that these events also affect T cell function and cytokine production after encountering 
TX527 treated DCs. A synergic suppressive effect of calcitriol and dexamethasone on in 
vitro LPS-induced maturation of DCs was also reported (27). 
Vitamin D exerts its effects on immune cells through its specific receptor (VDR). Vita-
min D-binding protein (DBP), a serum globulin, which is mainly produced by the liver, 
transports vitamin D metabolites to target tissues and cells. It also helps to regulate the 
bioavailability of calcitriol. On the target cell, calcitriol is released from DBP, enters the 
cell, interacts with VDR and shuttles from cytoplasm to the nucleus. Nuclear VDR is a 
ligand-activated transcription factor which is activated by calcitriol. Activated VDR fi-
nally activates the target genes. Calcitriol thus exerts its biological actions through 
VDR-mediated gene regulation (11,12,23,28,29). Gauzzi et al. (30) showed the central 
role of interferon regulatory factor 4 (IRF-4), which is a lymphoid and myeloid re-
stricted transcription factor of the IRF family, in calcitriol-mediated immunomodulation 
of DCs. Also it was revealed that calcitriol increases the expression of immunoglobulin-
like transcript 3 (ILT3) on human DCs three to six fold. This finding suggests the in-
volvement of ILT3 in the immunoregulatory properties of this active form of vitamin 
D3. Expression of ILT3 is associated with the induction of regulatory T cells which is 
crucial in the treatment and prevention of autoimmune diseases (19, 31). 
Griffin et al. (32) used VDR knockout mice to study the importance of VDR in DC 
maturation. They showed that DC modulation by a synthetic analog of calcitriol is VDR 
dependent and causes a persistent state of immaturity. They reported that compared with 
intact animals, VDR-deficient mice had hypertrophy of the subcutaneous lymph nodes 
and an increase in the number of mature DCs in the lymph nodes and not in the spleen. 
However we observed that IP injection of calcitriol affects both the size of the spleen 
and maturation of its DCs. 
DCs can either upregulate or downregulate the immune response depending on their 
subtype, degree of maturation and microenvironment. Induction of T cell response re-
quires both T cell receptor activation and costimulation (27). Hence a decrease in the 
expression of costimulatory molecules, which is accompanied by an immature state of 
DCs, reduces their T cell stimulatory potential. Our results which was consistent with in 
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vitro reports showed that calcitriol downregulates the expression of costimulatory mole-
cules on DCs. Therefore, the significant decrease in T cell activation rate which was ob-
served in MLR reaction following calcitriol-treatement of DCs was expectable. Gregori 
et al. (33) also orally administered mycophenolate mofetil in combination with 1, 25-
Dihydroxyvitamin D3 to mice in a transplantation model. They also showed the down-
regulation of costimulatory molecules in DCs from the graft area along with an induc-
tion of regulatory T cells.   
We also showed that CD8α expression, as a marker for lymphoid subsets of DCs which 
induce Th1 responses in mice, was downregulated, while CD11b expression, which is 
considered as a marker of Th2 inducing DCs, was increased. 
Dendritic cells are a heterogeneous population of immunocytes with diverse phenotypes 
and functions. Both in human and mice DCs are usually subdivided into at least two 
subtypes, based on their tissue localization and expression of surface markers (2,3). 
These subtypes of DCs are functionally distinct as well. In mice, lymphoid DCs 
(CD8α+, CD11b-) direct immune response towards Th1 pathway after antigen presenta-
tion and secretion of high amount of IL-12 and IFN-γ. However, myeloid DC's (CD8α-
and CD11b+) shift the immune function towards Th2 type and produce IL-4 and IL-10 
cytokines (4-8). 
Penna et al. (34) reported that calcitriol selectively affects myeloid DCs in humans. 
Based on their reports, after exposure of human DCs to calcitriol, the production of IL-
12 from myeloid DCs decreased and caused a significant reduction in their capacity to 
induce Th1 cells. Considering that human myeloid DCs are counterparts of mice lym-
phoid DCs, the work of Penna et al. is consistent with our findings, meaning that in both 
human and mice calcitriol shifts immune response toward a Th2 cytokine profile.  
In conclusion, calcitriol has several in vivo inhibitory effects on DC maturation and ex-
pression of costimulatory molecules. Also this compound induces an immune shift to-
ward Th2 cytokine profile. In fact the in vivo effects of calcitriol on DCs are compara-
ble with its in vitro effects. 
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